Skip to content
Evigrade
CriticalSystemic antimycotics. Imidazole derivatives×Highly selective α1A-adrenergic blocker

Updated · Methodology

Mechanism

The liver clears silodosin mainly through the enzymes CYP3A4, alcohol dehydrogenase and UGT2B7, and P-glycoprotein (P-gp) transports it. Substances that inhibit these enzymes and transporters, ketoconazole among them, can change the levels of silodosin and its active metabolite (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). Ketoconazole strongly inhibits CYP3A4 and can inhibit P-gp (ketoconazole SmPC, EMA). In an interaction study, ketoconazole 400 mg raised peak silodosin concentration 3.7-fold and the area under the curve (AUC) 3.1-fold (silodosin SmPC, EMA). The US label gives 3.8-fold and 3.2-fold (silodosin label, US Food and Drug Administration, FDA). The interaction is likely to be stronger at higher ketoconazole doses and shorter dosing intervals. In Cushing's syndrome, the daily ketoconazole dose reaches 1200 mg (ketoconazole SmPC, EMA).

Symptoms

The higher the silodosin level, the more likely postural hypotension becomes. Postural hypotension was the dose-limiting reaction in healthy men who took up to 48 mg of silodosin a day (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). It shows as dizziness on standing and, rarely, fainting (silodosin SmPC, EMA). The most common adverse effects of silodosin are ejaculation disorders: retrograde ejaculation and reduced or absent ejaculate (silodosin SmPC, EMA).

Management

The US silodosin label contraindicates the combination. It names ketoconazole among the strong CYP3A4 inhibitors that silodosin must not be taken with, and the interaction study used ketoconazole (silodosin label, US Food and Drug Administration, FDA). The European silodosin summary of product characteristics (SmPC) is softer but also advises against the pair: it does not recommend silodosin with strong CYP3A4 inhibitors, including ketoconazole (silodosin SmPC, European Medicines Agency, EMA). The ketoconazole documents do not name silodosin. Before starting ketoconazole, review all the patient's medicines. For each one, read its prescribing information on use with a strong CYP3A4 inhibitor (ketoconazole SmPC, EMA, and FDA label). At the first signs of postural hypotension, such as dizziness on standing, ask the patient to sit or lie down until the symptoms pass (silodosin SmPC, EMA). When starting silodosin, warn the patient about driving and operating machinery (silodosin FDA label). The contraindication applies to oral ketoconazole: in the European Union, ketoconazole tablets are used for endogenous Cushing's syndrome (ketoconazole SmPC, EMA). In adults, plasma ketoconazole was undetectable after the cream on the skin or the gel on the scalp, but measurable after the gel on the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ketoconazole

Other interactions with Silodosin